Skip to main content

Table 2 Candidate driver genes with significantly recurrent somatic mutations in mucinous ovarian tumors

From: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

  Exome cohort SMG prediction Validation cohort Overall
Gene Mutated samples Nonsense, frameshift indel, splice Inframe indel, missense OncodriveFM MuSiC q-value Mutated samples Nonsense, frameshift indel, splice Inframe indel, missense Mutated samples
  q-value FCPT LRT CT
KRAS 12 0 12 1.34 × 10−13 0 0 0 32 0 33 44/82
TP53 7 1 6 3.66 × 10−11 2.86 × 10−7 1.41 × 10−9 1.17 × 10−12 15 0 15 22/82
BRAF 6 0 6 2.45 × 10−8 7.77 × 10−7 0 6.18 × 10−12 4 0 5 10/82
CDKN2A 5 5 2 0.0043 1.20 × 10−10 0 7.93 × 10−17 5 5 0 10/63
RNF43 5 5 0 4.65 × 10−6 0.0009 0.0004 3 2 1 8/65b
ELF3 3 2 1 0.0079 0.0003 0.0004 1 1 0 4/65
ARID1A 2 2 0 0.0164 0.0933 2/24
DCLK1 2 0 2 0.0569 2/24
ERBB3 2 0 3 0.0014 0.0374 0 0 0 2/43
FBXW7 2 1 1 0.0207 2/24
GNAS a 2 0 2 9.05 × 10−8 3 0 3 5/81
KLF5 2 2 0 0.0164 0.0056 0.0536 0 0 0 2/43
LPHN3 2 0 2 0.0493 2/24
LRRK2 2 1 1 0.0997 2/24
TTF1 2 0 2 0.0569 2/24
  1. All non-synonymous mutations in listed genes were validated by Sanger sequencing
  2. CT convolution test, FCPT Fisher’s combined P-value test, LRT likelihood ratio test, SMG significantly mutated gene
  3. aOnly mutations involving the hotspot codon 201 are reported
  4. bIncludes samples from Ryland et al. [8] plus 16 additional samples